Pharminent

EMA’s CHMP backs Pfizer’s Xeljanz for rheumatoid arthritis

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Pfizer’s Xeljanz to treat rheumatoid arthritis (RA). http://processandproduction.pharmaceutical-business-review.com/news/emas-chmp-backs-pfizers-xeljanz-for-rheumatoid-arthritis-300117-5726409

Filed under: Arthritis